Caplyta phase 3 data show rapid, significant mania symptom relief in bipolar I by day 3, sustained to week 3, with tolerable adverse effects.
|Slideshows|August 12, 2019
Focus on Bipolar Disorder: 6 New Studies
Author(s)Leo Robert
Treatment failure risk is high, new biomarker of conversion from major depressive disorder, depression stifles creativity, and other recent findings are summarized here.
Advertisement
Advertisement
Related to this article
New real-world studies show Vraylar boosts depression relief, functioning, and quality of life in MDD and bipolar I patients beyond clinical trials.
Advertisement
Advertisement
Trending on Psychiatric Times
1
FDA Grants Breakthrough Device Designation to NET Recovery's Device for Stimulant Use Disorder
2
Using Psychotherapy for the Prevention of Relapse in Schizophrenia
3
The Adolescent Brain and Schizophrenia: What Research Reveals About Pruning, Dopamine, and Myelin
4
Positive Phase 2 Topline Results: Remlifanserin for the Treatment of Alzheimer Disease Psychosis
5